Kava Research

The following are research papers published over the decades on kava and its effects on various aspects of health. Select the topic and research paper you’d like to explore, and the document will open as a PDF file in your browser.

Pharmacologic Treatment of Opioid Use Disorder: A Review of Pharmacotherapy, Adjuncts, and Toxicity (Toce et al. 2018)
Novel Pharmacological Targets in Drug Development for the Treatment of Anxiety and Anxiety-Related Disorders (Sartori et al. 2019)
The Acute Effects of Kava and Oxazepam on Anxiety, Mood, Neurocognition; and Genetic Correlates: A Randomized, Placebo-controlled, Double-blind Study (Sarris et al. 2012)
The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebocontrolled, double-blind study (J Sarris 2012)
Kava in the Treatment of Generalized Anxiety Disorder A Double-Blind, Randomized, Placebo-Controlled Study (Stough et al. 2013)
Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial (Karen M. Savage 2015)
A-Napoleonic-homoeopath_1997_British-Homoeopathic-journal
Review: Kava extract reduces symptoms in adults with anxiety (Pittler MH, Ernst et al. 2000)
Complementary and Alternative Medicine Treatments for Generalized Anxiety Disorder: Systematic Review and Meta-analysis of Randomized Controlled Trials (Hrvoje Baric 2018)
Anxiolytic properties of compounds that counteract oxidative stress, neuroinflammation, and glutamatergic dysfunction: a review (Patricia Santos et al. 2019)
Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence (Jerome Sarris et al. 2011)
Kava /Kava administration reduces anxiety in perimenopausal women (Angelo Cagnacci et al. 2002)
A placebo-controlled study of Kava kava in generalized anxiety disorder (K.M. Connor et al. 2002)
Double blind clinical trial of a natural Kavapyrone Complex in elderly patients with Anxiety syndroms (Pietro de Nicola at al. 1992)
Effects-of-kava-on-benzodiazepine-ande-GABA-receptor-binding_1990_European-Journal-of-Pharmacology
Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin - A double-blind placebo-controlled study of four weeks treatment E. LEHMANN et al. 1996)
Enhanced efficacy and reduced side effects of diazepam by kava combination (Rasha A. Tawfiq et al. 2014)
Kava extract for treating anxiety (Cochrane 2002)
Effect of Phytoestrogen on Depression and Anxiety in Menopausal Women: A Systematic Review (Abolfazl Fattah 2017)
THE ROLE OF OXIDATIVE STRESS IN ANXIETY DISORDER: CAUSE OR CONSEQUENCE? (Alessandra das Graças Fedoce et al. 2018)
Treatment of anxiety, tension and restlessness states with Kava special extract WS® 1490 in general practice: A randomized placebo-controlled double-blind multicenter trial (M. Gastpar et al. 2003)
Kava Treatment in Patients with Anxiety (F. P. Geier et al. 2004)
Gleitz et al 1996_European-Neurops
Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats (Natalie R. Bruner et al. 2009)
Health policy versus kava (Piper methysticum): Anxiolytic efficacy may be instrumental in restoring the reputation of a major South Pacific crop (Michael Thomsen et al. 2020)
Jorm 2007 Kava Anxiety review
A Behavioral Survey of the Effects of Kavalactones on Caenorhabditis elegans Neuromuscular Transmission (Bwarenaba B Kautu et al. 2017)
Aqueous Extract of Kava Found Anxiolytic Even in Depressed Subjects (Dennis Awang et al. 2009)
Pittler MH, Ernst E. Kava extract for treating anxiety (Cochrane Review). In: The Cochrane Library, Issue 4, 2002)
Kava in the Treatment of Generalized Anxiety Disorder A Double-Blind, Randomized, Placebo-Controlled Study (Jerome Sarris et al. 2013)
Kava decreases the stereotyped behavior induced by amphetamine in mice Barbara Nunes Krum et al. 2021)
Kava-kava and anxiety: Growing knowledge about the efficacy and safety (Anna Rita Bilia et al. 2001)
Kavalactones and the endocannabinoid system: The plant-derived yangonin is a novel CB1 receptor ligand (Alessia Ligresti et al. 2012)
Wirksamkeit eines Kava Spezial Extraktes bei Patienten mit Angst-, Spannungs- und Erregungszustaenden nicht-psychotischer Genese (E. Kinzler et al. 1991)
Der Einfluss natuerlicher 5,6-hydrierter Kawa-Pyrone auf isolierte Herzpraeparate und Ihre antifibrillatorische Wirkung am Ganztier (Kretzschmar et al. 1968)
Randomized, dose-controlled double-blind trial: Efficacy of an ethanolic kava (Piper methysticum rhizome) extract for the treatment of anxiety in elderly patients (Kenny Kuchta et al. 2017)
Nutritional and herbal supplements for anxiety and anxiety-related disorders: systematic review (Shaheen E Lakhan et al. 2010)
The efficacy of Cavain in patients suffering from anxiety (Lehmann et al. 1989)
Efficacy of a special Kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin - A double blind placebo-controlled study of four weeks treatment (Lehmann et al. 1996)
D,L-Kavain im Vergleich zu Oxazepam bei Angstzustaenden (Lindenberg et al. 1990)
Interaction of various Piper methysticum Cultivars with CNS Receptors in vitro)
Neurobehavioral and toxicological activities of two potentially CNS-acting medicinal plants of Piper genus (Janaina Jardim Lopes et al. 2010)
Kava for Generalized Anxiety Disorder: A Review of Current Evidence (Soo Liang Ooi et al. 2018)
Occupational stress and burnout among Surgeons in Fiji (Rajeev Patel et al. 2017)
Randomized, dose-controlled double-blind trial: Efficacy of an ethanolic kava (Piper methysticum rhizome) extract for the treatment of anxiety in elderly patients (Kenny Kuchta et al. 2017)
Kava Treatment in Patients with Anxiety (F. P. Geier et al. 2004)
The Use of Kava and Cognitive-Behavior Therapy in the Treatment of Panic Disorder (Frank M. Dattilio et al. 2002)
The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum (J. Sarris et al. 2009)
Time for a reassessment of the use of Kava in anxiety? (Complementary Therapies in Medicine (2009)
Kava extract versus placebo for treating anxiety (Review) (Pittler MH, Ernst E - Cochrane Library 2003)
Kavain, the Major Constituent of the Anxiolytic Kava Extract, Potentiates GABAA Receptors: Functional Characteristics and Molecular Mechanism (Han Chow Chua et al. 2016)
Anxiolytic-like effects of Kava-Kava in the elevated plus maze test—a comparison with diazepam (Andre´ Rex et al. 2002)
Kava Anxiety Depression Spectrum Study (KADSS): A mixed methods RCT using an aqueous extract of Piper methysticum (J. Sarris et al. 2009)
Kava in the Treatment of Generalized Anxiety Disorder A Double-Blind, Randomized, Placebo-Controlled Study (Jerome Sarris et al. 2013)
The Kava Anxiety Depression Spectrum Study (KADSS): a randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum (J. Sarris et al. 2009)
Kava for generalised anxiety disorder: A 16-week double-blind, randomised, placebo-controlled study. (Sarris J et al. 2019)
GABA‐modulating phytomedicines for anxiety: A systematic review of preclinical and clinical evidence (Karen Savage et al. 2017)
Kava for the treatment of generalised anxiety disorder (K-GAD): study protocol for a randomised controlled trial (Karen M. Savage et al. 2015)
The effectiveness and safety of Kava Kava for treating anxiety symptoms: A systematic review and analysis of randomized clinical trials (Katelyn Smith et al. 2018)
Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review (Jeffrey R. Strawn et al. 2018)
The effect of most important medicinal plants on two important psychiatric disorders (anxiety and depression)-a review (Kourosh Saki et al. 2014)
The Use of Kava and Cognitive-Behavior Therapy in the Treatment of Panic Disorder (Frank M. Dattilio et al. 2002)
Treatment of anxiety, tension and restlessness states with Kava special extract WS® 1490 in general practice: A randomized placebo-controlled double-blind multicenter trial (M. Gastpar et al. 2003)
Kava-kava Extract WS 1490 versus Placebo in Anxiety Disorders - A Randomized Placebo-controlled 25-week Outpatient Trial (H.-P. Volz et al. 1997)
Behandlung von angst-patientendoppelblindstudie: kava-spezialextrakt WS 1490 versus Benzodiazepine (Woelk et al. 1993)
Kava /Kava administration reduces anxiety in perimenopausal women (Angelo Cagnacci et al. 2002)
Effect of Phytoestrogen on Depression and Anxiety in Menopausal Women: A Systematic Review (Abolfazl Fattah 2017)
Kava􏰀/Kava administration reduces anxiety in perimenopausal women (Cagnacci et al 2002)
Effect of Phytoestrogen on Depression and Anxiety in Menopausal Women: A Systematic Review (Fattah 2017)
Double-Blind Clinical Trial of Natural Kavapyrone Complex in Elderly Patients with Anxiety Syndromes (Nicola 1992)
Kava: La Mise en Garde de Santé Canada et la Conférence Canadienne de Consensus sur la Ménopause et L’Ostéoporose 2000/2001
Correction to: Pharmacists’ Confidence When Providing Pharmaceutical Care on Anticoagulants, a Multinational Survey (Papastergiou et al. 2018)
Computer-assisted Optimization in the Development of a High- Performance Liquid Chromatographic Method for the Analysis of Kava Pyrones in Piper Methysticum Preparations (Schmidt et al. 2002)
ANALYSIS FOR KAWA PYRONES IN EXTRACTS OF PIPER METHYSTXUM* (RICHARD L. YOUNG et al. 1966)
Analysis of kavalactones from Piper methysticum (kava-kava) (Anna Rita Bilia et al. 2004)
Analysis of plant extracts by NIRS: simultaneous determination of kavapyrones and water in dry extracts of Piper methysticum Forst. (M. Gaub et al. 2004)
CHROMATOGRAPHE SURE COUCHES EPAISSES NON LIEES DES CONSTITUANTS DU RHIZOME DE PIPER METHYSTICUM (PER JOESSANG ET Al. 1967)
Comparison of kava (Piper methysticum Forst.) varieties by UV absorbance of acetonic extracts and high-performance thin-layer chromatography (Vincent Lebot et al. 2016)
Computer-assisted optimization in the development of a highperformance liquid chromatographic method for the analysis of kava pyrones in Piper methysticum preparations (Alexander H. Schmidt et al. 2002)
Contribution to the quantitative and enantioselective determination of kavapyrones by high-performance liquid chromatography on ChiraSpher NT material (Georg Boonen et al. 1997)
Standard Method Performance Requirements (SMPRs®) 2018.005: Determination of Kavalactones and/or Flavokavains from Kava (Piper methysticum) (Steven J. Dentali at al. 2018)
Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC) (V. Lebot et al. 2013)
Determination of kava lactones in food supplements by liquid chromatography–atmospheric pressure chemical ionisation tandem mass spectrometry (I. Bobeldijk et al. 2005)
Erratum to “Computer-assisted optimization in the development of a high-performance liquid chromatographic method for the analysis of kava pyrones in Piper methysticum preparations” (Alexander H. Schmidt et Imre Molnar 2006)
Flachsmann HPLC-Bestimmung der Kava-Pyrone in kava-Kava extrakt 27-02-1987
High-performance liquid chromatography assays for desmethoxyyangonin, methysticin, kavain and their microsomal metabolites Analysis of desmethoxyyangonin, methysticin, kavain and their microsomal metabolites (Shuang Fu et al. 2008)
HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY OF KAVA LACTONES FROM PIPER METHYSTICUM (ROGER M. SMITH et al. 1984)
Journal of Chromatography B, 826 (2005) 46–49 HPLC analysis of flavokavins and kavapyrones from Piper methysticum Forst. (Oliver Meissner, Hanns Haeberlein 2005)
Kavalactones from Piper methysticum, and their 13C NMR spectroscopic analyses H. Ranjith W. et al. 2002)
Quantification of Kavalactones and Determination of Kava (Piper methysticum) Chemotypes Using Near-Infrared Reflectance Spectroscopy for Quality Control in Vanuatu (PRIVAT LASME et al. 2008)
Colorimetric assessment of kava (Piper methysticum Forst) quality (Tiphaine Lhuissier et al. 2017)
Quantitative Determination of Lactones in Piper methysticum (Kava-Kava) by Supercritical Fluid Chromatography (Adele Murauer et Markus Ganzera 2017)
Janus Electrochemistry: Simultaneous Electrochemical Detection at Multiple Working Conditions in a Paper-based Analytical Device (Siriwan Nantaphol et al. 2019)
Chemical and in vitro toxicity analysis of a supercritical fluid extract of Kava kava (Piper methysticum) (Greg E. Petersen et al. 2019)
Inhibition of Cytochrome P450 3A4 by Extracts and Kavalactones of Piper methysticum (Kava-Kava) (Matthias Unger et al. 2003)
Rapid differentiation of Piper methysticum (kava) plant parts using single point and imaging vibrational spectroscopy (Ramoagi T. Segone et al. 2020)
Reversed-phase high-performance liquid chromatographic method for quantitative analysis of the six major kavalactones in Piper methysticum (Yu Shao et al. 1998)
A UHPLC-UV Method Development and Validation for Determining Kavalactones and Flavokavains in Piper methysticum (Kava) (Yijin Tang and Christine Fields 2019)
Testing for kavain in human hair using gas chromatography–tandem mass spectrometry (M. Villain et al. 2003)
A stable isotope dilution tandem mass spectrometry method of major kavalactones and its applications (Yi Wang et al. 2018)
Evidence for Conspecificity of Piper methysticum Forst. f. and Piper wichmannii C. DC. (Lebot et al. 1996)
GENETIC CONTROL OF KAVALACTONE CHEMOTYPES IN PIPER METHYSTICUM CULTIVARS (VINCENT LEBOT and JOEL LEVESQUE 1996)
Identification of factors determining kavalactone content and chemotype in Kava (Piper methysticum Forst. f.) (Patricia Simeoni, Vincent Lebot 2001)
Inhaltsstoffe von Piper methysticum Forster - eine thermomikroskopische Studie (Langhammer 1970)
Validation of Piper methysticum var. wichmannii (Piperaceae) (Wendy L. Applequist et Vincent Lebow 2006)
A Novel Kavalactone Derivative Protects Against H2O2-induced PC12 Cell Death via Nrf2/ARE Activation (Tanaka et al. 2010)
The Flavokawains: Uprising Medicinal Chalcones (Abu et al. 2013)
Flavokawain A Induces Apoptosis in MCF-7 and MDAMB231 and Inhibits the Metastatic Process In Vitro (Nadiah Abu et al. 2014)
In vivo antitumor and antimetastatic effects of flavokawain B in 4T1 breast cancer cell-challenged mice (Nadiah Abu et al. 2015)
Kava, a Tonic for Relieving the Irrational Development of Natural Preventive Agents (Rajesh Agarwal and Gagan Deep 2018)
Identification of methysticin as a potent and non-toxic NF-􀈛B inhibitor from kava, potentially responsible for kava's chemopreventive activity (Ahmad Ali Shaik et al. 2009)
Chalcone flavokawain B induces autophagic-cell death via reactive oxygen species-mediated signaling pathways in human gastric carcinoma and suppresses tumor growth in nude mice (Chia‑Ting Chang et al. 2017)
Cyclooxygenase enzyme inhibitory compounds with antioxidant activities from Piper methysticum (kava kava) roots (D. Wu et al. 2002)
Dietary feeding of flavokawain A, a Kava chalcone, exhibits a satisfactory safety profile and its association with enhancement of phase II enzymes in mice (Xuesen Li et al. 2014)
Traditional preparations of kava (Piper methysticum) inhibit the growth of human colon cancer cells in vitro (LS Einbond et al. 2016)
Flavokawain B, a novel, naturally occurring chalcone, exhibits robust apoptotic effects and induces G2/M arrest of a uterine leiomyosarcoma cell line (Ramez N. Eskander et al. 2012)
Evaluation of commercial kava extracts and kavalactone standards for mutagenicity and toxicity using the mammalian cell gene mutation assay in L5178Y mouse lymphoma cells (Paul Whittaker et al. 2007)
Flavokawains B and C, melanogenesis inhibitors, isolated from the root of Piper methysticum and synthesis of analogs (Hye-Jin Jeong et al. 2014)
Adenosine 5'‐monophosphate‐activated protein kinase‐dependent mTOR pathway is involved in flavokawain B‐induced autophagy in thyroid cancer cells (Qin He et al. 2018)
Identification of methysticin as a potent and non-toxic NF-jB inhibitor from kava, potentially responsible for kava’s chemopreventive activity (Ahmad Ali Shaik et al. 2009)
Inhibition of TNFa-induced activation of nuclear factor kB by kava (Piper methysticum) derivatives (Florence Folmer et al. 2005)
Isolation and synthesis of TNF-a release inhibitors from Fijian kawa (Piper methysticum) (T. Hashimoto et al. 2003)
Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin (Danielle D. Jandial et al. 2017)
Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice. (Johnson TE et al. 2011)
The Combination of Flavokawain B and Daunorubicin Induces Apoptosis in Human Myeloid Leukemic Cells by Modifying NF-ĸB (JAE JIN LEE et al. 2018)
Kava Blocks 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanoneinduced Lung Tumorigenesis in Association with Reducing O6- methylguanine DNA Adduct in A/J Mice (Pablo Leitzman et al. 2014)
Kava Components Down-Regulate Expression of AR and AR Splice Variants and Reduce Growth in Patient-Derived Prostate Cancer Xenografts in Mice (Xuesen et al. 2012)
Flavokawain B targets protein neddylation for enhancing the anti-prostate cancer effect of Bortezomib via Skp2 degradation (Xuesen Li et al. 2019)
KAVA chalcone, Flavokawain A, inhibits urothelial tumorigenesis in the UPII-SV40T transgenic mouse model (Zhongbo Liu et al. 2013)
Kavalactone yangonin induces autophagy and sensitizes bladder cancer cells to flavokawain A and docetaxel via inhibition of the mTOR pathway (Zhongbo Liu et al. 2017)
Society of Interventional Radiology Multisociety Consensus Position Statement on Prostatic Artery Embolization for Treatment of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: From the Society of Interventional Radiology, the Cardiovascular and Interventional Radiological Society of Europe, Soci et e Française de Radiologie, and the British Society of Interventional Radiology (Justin P. McWilliams et a. 2019)
Induction of Apoptosis and Cell Cycle Arrest by Flavokawain C on HT-29 Human Colon Adenocarcinoma via Enhancement of Reactive Oxygen Species Generation, Upregulation of p21, p27, and GADD153, and Inactivation of Inhibitor of Apoptosis Proteins (Chung-Weng Phang et al. 2017)
Kava and its Kavalactones Inhibit Norepinephrine-induced Intracellular Calcium Influx in Lung Cancer Cells (Jordy F. Botello et al. 2019)
The protective effects of Kava (Piper Methysticum) constituents in cancers: A systematic review (Antonio Celentano 2019)
The In Vitro and In Vivo Antiangiogenic Effects of Flavokawain (B Mariana C. Rossette et al. 2017)
The Correlation between Cancer Incidence and Kava Consumption (Gregory D. Steiner 2006)
Mechanisms of Action and Structure-Activity Relationships of Cytotoxic Flavokawain Derivatives (Charlotte Thieury 2017)
Traditional preparations of kava ( Piper methysticum ) inhibit the growth of human colon cancer cells in vitro (L.S. Einbond et al. 2016)
Reduction in Colon Cancer Risk by Consumption of Kava or Kava Fractions in Carcinogen-Treated Rats (Julie Triolet et al. 2012)
Inhibition of glioma growth by flavokawain B is mediated through endoplasmic reticulum stress induced autophagy (Jiwei Wang et al. 2018)
EXTRACTS AND KAVALACTONES OF PIPER METHYSTICUM G. FORST (KAVA-KAVA) INHIBIT P-GLYCOPROTEIN IN VITRO (Johanna Weiss et al. 2005)
Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma (Yidan Zhang et al. 2018)
Flavokawain A, a Novel Chalcone from Kava Extract, Induces Apoptosis in Bladder Cancer Cells by Involvement of Bax Protein-Dependent and Mitochondria-Dependent Apoptotic Pathway and Suppresses Tumor Growth in Mice (Xiaolin Zi and Anne R. Simoneau 2005)
Quality of Reporting of Randomized Controlled Trials of Herbal Medicine Interventions (Gagnier et al. 2006)
Kava-Kava: Eine Luecke die keiner wollte (Volker Faust 2002)
Kava: A Comprehensive Review of Efficacy, Safety, and Psychopharmacology (Sarris et al. 2011)
The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebocontrolled, double-blind study (J Sarris et al. 2012)
A kavalactone derivative inhibits lipopolysaccharide-stimulated iNOS induction and NO production through activation of Nrf2 signaling in BV2 microglial cells (Riyako Terazawa et al. 2013)
Der Einfluss von D,L-Kavain (Neurinoka) auf Konzentrationsfaehigkeit. Kurzzeitgedaechtnis, Reaktionssicherheit und Geschwindigkeit (L. Ambrozi 1979)
Saccade and cognitive impairment associated with kava intoxication (Sheree Cairney 2003)
Double-Blind Clinical Trial of Natural Kavapyrone Complex in Elderly Patients with Anxiety Syndromes (Pietro de Nicola 1993)
Discriminative-stimulus and time-course effects of kava-kava (Piper methysticum) in rats (Natalie R. Bruner et al. 2008)
EFFECT OF KAVA EXTRACT AND INDIVIDUAL KAVAPYRONES ON NEUROTRANSMITTER LEVELS IN THE NUCLEUS ACCUMBENS OF RATS (SIEDY SAELLSTROEM BAUM et al. 1998)
Effects of (6)-kavain on voltage-activated inward currents of dorsal root ganglion cells from neonatal rats (K. Schirrmachera et al. 1998)
EFFECTS OF KAWAIN AND DIHYDROMETHYSTICIN ON FIELD POTENTIAL CHANGES IN THE HIPPOCAMPUS (JORG WALDEN et al. 1997)
Extract of kava ( Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents (Cord Backhauss and Josef Krieglstein 1992)
Oral administration of methysticin improves cognitive deficits in a mouse model of Alzheimer's disease (Athanassios Fragoulisa et al. 2017)
Saccade and Cognitive Function in Chronic Kava Users (Sheree Cairney et al. 2003)
KAVA EXTRACT INGREDIENTS, (+)-METHYSTICIN AND (&)-KAVAIN INHIBIT VOLTAGE-OPERATED Na+-CHANNELS IN RAT CA1 HIPPOCAMPAL NEURONS (E. I. MAGURA et al. 1997)
KAVA PYRONES EXERT EFFECTS ON NEURONAL TRANSMISSION AND TRANSMEMBRANEOUS CATION CURRENTS SIMILAR TO ESTABLISHED MOOD STABILIZERS - A REVIEW (HEINZ GRUNZE et al. 2001)
Kava reloaded? The tip of a regulatory iceberg (Karin Kraft 2015)
Uptake to Mouse Brain of Four Compounds Present in the Psychoactive Beverage Kava (J. Keledjian et al. 1998)
Kavain als Psychopharmakon (Kretschmer 1970)
Die Wirkung von Neuronika auf die motorische Reaktionszeit und die visuell-mentale Verarbeitungszeit (H. Krueger & G. Kell 1977)
Neurobehavioral and toxicological activities of two potentially CNS-acting medicinal plants of Piper genus (Janaina Jardim Lopes et al. 2010)
Paroxetine long-term safety and efficacy in panic disorder and prevention of relapse: A double blind study (R. Judge et al. 1996)
Phytomedicines for Prevention and Treatment of Mental Health Disorders (Patricia L. Gerbarg and Richard P. Brown 2013)
Phytotherapy and psychiatry: Bibliometric study of the scientific literature from the last 20 years (P. Garcia-Garcia et al. 2008)
Herbal medicines in the treatment of psychiatric disorders: 10‐year updated review (Jerome Sarris et al. 2017)
Plants and the central nervous system (E.A. Carlini 2003)
Post-insult exposure to (6) kavain potentiates N-methyl-D-aspartate toxicity in the developing hippocampus (Patrick J. Mulholland and Mark A. Prendergast 2002)
Herbal medicines in the treatment of psychiatric disorders: 10‐year updated review (Jerome Sarris et al. 2017)
The effect of most important medicinal plants on two importnt psychiatric disorders (anxiety and depression)-a review (Kourosh Saki et al. 2014)
The influence of (9)-kavain on population spikes and long-term potentiation in guinea pig hippocampal slices (J.M. Langosch et al. 1997)
The Use of Kava and Cognitive-Behavior Therapy in the Treatment of Panic Disorder (Frank M. Dattilio 2002)
The use of Scutellaria lateriflora: A pilot survey amongst herbal medicine practitioners (Christine Brock et al. 2012)
Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava) (Richard Thompson et al. 2004)
Comparison of Subcritical Water and Organic Solvents for Extracting Kavalactones from Kava Root (Kubátova ́ et al. 2001)
Cyclodextrins as carriers for kavalactones in aqueous media: Spectroscopic characterization of (S)-7,8-dihydrokavain and -cyclodextrin inclusion complex (G. Pescitelli et al. 2010)
Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC) (V. Lebot et al. 2014)
Evidence for Conspecificity of Piper methysticum Forst. f. and Piper wichmannii C. DC. (VINCENT LEBOT and JOEL LEVESQUE 1996)
GENETIC CONTROL OF KAVALACTONE CHEMOTYPES IN PIPER METHYSTICUM CULTIVARS (VINCENT LEBOT and JOEL LEVESQUE 1996)
Identification of factors determining kavalactone content and chemotype in Kava (Piper methysticum Forst. f.) (Patricia Simeoni and Vincent Lebot 2001)
Hawaiian ‘Awa Views of an Ethnobotanical Treasure - Edited by Ed Johnston and Helen Rogers - (Klaus Dragull et al. 2006)
Kava Producer's Guide (Secretariat of the Pacific Community, Suva, Fiji Islands 2001)
Kava root (Piper methysticum L.) as a potential natural herbicide and fungicide (Tran DangXuan et al. 2003)
Leberschäden durch
Medikamente und Phytopharmaka:Sind sie voraussehbar? (Bernhard H. Lauterburg 2002)
The Quality of Kava Consumed in the South Pacific (Vincent Lebot 2004)
The Origin and Distribution of Kava (Piper methysticum): A Phytochemical Approach (Lebot and Levesque 1989)
Genetic Control of Kavalactone Chemotypes in Piper Methysticum Cultivars (Vincent Lebot and Joel Levesque 1996)
Evidence of Conspecificity of Piper methysticum (Vincent Lebot and Joel Levesque 1996)
Geographic Survey of Genetic Variation in Kava (V. Lebot et al. 1991)
Lebot et al 1992 Kap 1-2
Lebot et al 1992 Kap 3-4
Lebot et al 1992 Kap 5-6
Lebot et al 1992 Kap 7-Ende
Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC) (V. Lebot et al. 2013)
Kava Praeparate im Internethandel (Lechtenberg et al 2008)
Kava Pirates in Vanuatu (Lamont Lindstrom 2006)
Quality Aspects of Traditional and Industrial Kava-Extracts (Loew & Franz 2003)
Muscodor brasiliensis sp. nov. produces volatile organic compounds with activity against Penicillium digitatum (Lorena C. Pena et al. 2019)
Interaction of Various Piper methysticum Cultivars with CNS Receptors in vitro (Long Doan Dinh et al. 2000)
Kavalactone content and chemotype of kava beverages prepared from roots and rhizomes of Isa and Mahakea varieties and extraction efficiency of kavalactones using different solvents (Jun Wang et al. 2015)
Piperidine alkaloids from Piper methysticum (Klaus Dragulla et al. 2003)
The Perils of Unmanaged Export Growth: The Case of Kava in Fiji (Naren Prasad Research Co-ordinator, United Nations 2006)
Preliminary Characterization of Aqueous Extracts of P+er methysticum (Kava, Kawa Kawa) By MAUREEN J. O’HARA et al. 1965)
Pressurized fluid extraction of carotenoids from Haematococcus pluvialis and Dunaliella salina and kavalactones from Piper methysticum (Judith R. Denery et al. 2003)
Qualitative and quantitative micellar electrokinetic chromatography of kavalactones from dry extracts of Piper methysticum Forst. and q commercial drugs (Matthias Lechtenberg et al. 1999)
Quality aspects of traditional and industrial Kava-extracts (D. Loew and G. Franz 2003)
Towards synthesis of kavalactone derivatives (Patrícia A. Amaral et al. 2008)
Isolation and Purification of Potent Growth Inhibitors from Piper methysticum Root (Truong Mai Van et al. 1991)
Efficacy of Extracting Solvents to Chemical Components of Kava (Piper methysticum) Roots (Xuan et al. 2008)
Piper methysticum extraction commercial KAVA EXTRACT
Efficacy of extracting solvents to chemical compounds of kava (Piper methysticum) root (Tran Dang Xuan 2008)

Kava Research

Addiction

Anxiety

Anticoagulent

Analytical

Botany

Cancer

Clinical Trials

Cognitive Function

Commercial Sources

Commercial Sources and Handling

Constituents

Depression

Fibrotic

History

Inflammation

International status

Ischemia

Liver

Ocular

Osteoperosis

Other Effects

Peridontal

Pharmacokinetics

Pharmacology

Regulatory

Reviews

Safety

Seizure-Spasmolytic

Sleep

Standards

Traditional